Zimbabwe's health authorities on Thursday began administering the long-acting HIV prevention drug lenacapavir, making the ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new Phase 3 ARTISTRY-1 and ARTISTRY-2 trial data at CROI 2026 showing a treatment switch to an investigational, single-tablet ...

An initial consignment of 19, 200 doses of Lanacapavir, a six-monthly HIV prevention injection drug, has arrived in Uganda, ...

A new, daily oral tablet that combines two current HIV treatment medications, bictegravir and lenacapavir (BIC/LEN), could ...

At 48 weeks, 1% of participants in both groups had an HIV-1 RNA level of 50 copies per milliliter or higher, meeting the prespecified noninferiority margin of 4%. Rates of viral suppression below 50 ...

Dar es Salaam. Tanzania has officially registered Lenacapavir, a long-acting injectable drug for the prevention and control of HIV, marking what officials describe as a significant milestone in the ...

Gilead Sciences posted results from a Phase 3 trial showing its HIV treatment was effective. The trial of bictegravir 75 mg/lenacapavir 50 mg was also well-tolerated and demonstrated the potential to ...

Zimbabwe's health authorities began administering the long-acting HIV prevention drug lenacapavir, making the country one of ...

The US launches long-acting HIV prevention drug lenacapavir in Zimbabwe, aiming to support thousands of people.

Zimbabwe is one of the world's first countries to roll out lenacapavir, a long-acting HIV prevention drug that is administered only twice a year.

Zimbabwe has launched lenacapavir, an HIV prevention drug administered biannually, aiming to curb infections. While offering ...

In the global fight against HIV, the "holy grail" has long been the quest for a prevention method that is highly effective, discreet, and easy to maintain.